Iovance reports Q3 net loss of $113.8M; BLA for lifileucel on track with PDUFA Feb 24, 2024

IOVANCE BIOTHERAPEUTICS, INC.

2023-Q3 EPS reported -$1.44 revenue$707,000

Net loss of $113.8M ($0.46/share) vs $99.6M ($0.63/share) in Q3 2022; revenue of $0.5M from Proleukin acquisition.
FDA Priority Review of lifileucel BLA on track; PDUFA date Feb 24, 2024; pre-approval inspections completed.
Onboarding completed at ~30 ATCs for potential U.S. commercial launch of lifileucel as first approved TIL therapy.
Cash position of $427.8M at Sept 30, 2023; raised ~$203.2M in Q3 from offerings; cash expected to fund operations into 2025.
Regulatory submissions for lifileucel in Europe and Canada planned for 2024; IOV-LUN-202 NSCLC trial enrollment on track for completion H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IOVANCE BIOTHERAPEUTICS, INC. reported financial results for third quarter and year-to-date 2023.

Period: third quarter and year-to-date 2023
Result: reported results

Exact text from the filing

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-115226

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.